Relmada (RLMD) Q3 2026 Earnings Call Transcript

Relmada (RLMD) reported Q3 2026 progress, including IND submissions for NDV-01 and sepranolone by year-end. NDV-01 showed 86% 18-month CR rate in NMIBC, with favorable safety. Phase 3 trials planned. Cash position of $202.1M expected to fund operations through 2029. Net loss was $13.9M, up from $10.1M YoY.

Original reporting
Published Nov 13, 2026, 5:43 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 5:50 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Relmada (RLMD) Q3 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$RLMDBullishMed
01

Why it matters

The disclosed Phase 2 durability data and IND filing timeline provide fresh, material information that could move the stock, especially given the company's cash position to fund upcoming trials.

02

Market read

First‑time disclosure of robust Phase 2 outcomes and IND plans makes this a high‑novelty biotech news item with potential short‑term price impact.

03

What to watch

Cash runway is sufficient, but the company remains loss‑making; dilution risk if additional capital is needed.

Relevance 8/10Novelty 8/10Timing: post‑earnings release today

Background

Relmada (RLMD) held its Q3 2026 earnings call, presenting updated financials and detailed clinical progress on its lead candidates NDV‑01 (bladder cancer) and sepranolone (Prader‑Willi syndrome).

Company-level read

Ticker impact

$RLMDBullishHigh confidence
Context

Relmada reported Phase 2 18‑month data for NDV‑01 showing 86% CR durability and announced IND filing plans for year‑end 2026, plus cash runway to 2029.

Expected impact

likely upward pressure as investors price in successful trial data and upcoming IND filing.

Evidence & confidence

Data are first‑time disclosed, clinically material, and indicate a clear path to Phase 3, which typically lifts biotech stocks.

Market effects

Strengthens the oncology‑focused biotech sector with a new intravesical therapy candidate.

U.S. biotech market may see modest gains as investors reassess early‑stage oncology pipelines.

Limited to biotech investors; no broad macro impact.

Counterpoint

If Phase 3 enrollment delays occur, the stock could face disappointment despite strong Phase 2 data.

Key entities

  • Relmada Therapeutics

    Biopharma developing NDV‑01 and sepranolone.

  • NDV‑01

    Sustained‑release intravesical formulation for NMIBC.

Related articles

$RLMDHigh

Relmada Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

RELMADA THERAPEUTICS, INC. (RLMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Relmada Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update ● NDV-01 CMC program on track to submit the IND by year-end 2026, with initiation of the registrational Phase 3 SPECTRUM program upon IND clearance ● Long-term extension ND

$RLMDMed

Relmada (RLMD) Q2 2026 Earnings Call Transcript

Relmada Therapeutics (RLMD) reported Q2 2026 results and an execution update. Cash was $217.7M at June 30, 2026, funding operations through 2029. Net loss was $12.9M ($0.11/share). Management expects IND filings for NDV-01 and sepranolone by end-2026 and Phase 3 RESCUE enrollment to start after IND clearance.

$RLMDMed

Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

RELMADA THERAPEUTICS, INC. (RLMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update ● Advancing NDV-01 toward IND filing expected by year-end 2026 with GMP manufacturing of clinical trial material underway. Initiation of the Phase 3 RESCUE registrational

$WMTHighAI 8/10

Walmart Has Raised Its Dividend 53 Straight Years. I'd Buy It Before December and Never Sell.

Walmart (WMT) reported better-than-expected sales and profits, raised its full-year forecast, and announced 53 consecutive years of dividend increases. Despite this, its stock fell 2% in early trading. The company's omnichannel model, advertising business, and AI shopping assistant contributed to its growth, while rising diesel prices and slowing same-store sales growth pose challenges. Walmart's dividend is payable to shareholders of record on December 11.